Prognostic Factors and Survival in Primary Central Nervous System Lymphoma: A Population-Based Study
Table 4
Univariate and multivariate survival analysis in immunocompromised patients with non-DLBCL.
Variable
Univariate analysis
Multivariate analysis
HR (95% CI)
HR (95% CI)
Age (years)
<60
Reference
≥60
0.599 (0.305–1.176)
0.136
Race
White
Reference
Black
1.029 (0.766–1.382)
0.848
Other (American Indian/AK native, Asian/Pacific Islander)
2.129 (0.936–4.841)
0.071
Gender
Female
Reference
Male
0.874 (0.568–1.346)
0.541
Dates of diagnosis
1973–1984
Reference
1985–1995
1.396 (0.344–5.661)
0.641
1996–2006
1.056 (0.257–4.347)
0.939
2007–2014
2.218 (0.518–9.505)
0.283
Primary site
Brain
Reference
Meninges/cranial nerves
1.068 (0.439–2.598)
0.885
Spine
0.784 (0.363–1.690) 0.620
0.534
Other
(0.414–0.929)
0.021
Laterality
Not a paired site
Reference
Paired site (left/right—origin of primary)
1.383 (0.905–2.115)
0.134
Lymphoma Ann Arbor stage
I–II
Reference
III–IV
0.968 (0.708–1.322)
0.836
Unknown
0.938 (0.495–1.779)
0.846
Radiation
No
Reference
Yes
0.803 (0.617–1.046)
0.104
Unknown
0.454 (0.111–1.846)
0.270
Chemotherapy
No
Reference
Reference
Yes
0.384 (0.273–0.539)
<0.001
0.384 (0.273–0.539)
<0.001
Insurance status
Uninsured
Reference
Insured/any Medicaid
0.349 (0.046–2.631)
0.307
Insurance status unknown
0.222 (0.031–1.605)
0.136
Marital status
Never married
Reference
Married
0.635 (0.430–0.936)
0.022
Ever married (divorced, separated, and widowed)
0.885 (0.531–1.477)
0.641
Unknown
2.138 (0.788–5.799)
0.136
OS: overall survival; HR: hazard ratio; CI: confidence interval; SEER: Surveillance, Epidemiology, and End Results; DLBCL: diffuse large B cell lymphoma; PCNSL: primary central nervous system lymphoma.
